Shire, Teva Call Truce In Fight Over Generic ADHD Drug

Law360, New York (May 31, 2013, 7:33 PM EDT) -- A Shire PLC unit said Friday that it had reached a settlement with Teva Pharmaceuticals USA Inc. resolving allegations that Teva infringed two patents for the attention deficit hyperactivity disorder drug Intuniv.

The deal granted Teva — which the suit accused of infringing the patents by seeking U.S. Food and Drug Administration approval of its generic version of the drug — a license to market either its own form of Intuniv or authorized generics made by Shire as of 2015.

Shire sued Teva in Delaware federal...
To view the full article, register now.